Function of COX-2 and prostaglandins in neurological disease.

Function of COX-2 and prostaglandins in neurological disease. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Function of COX-2 and prostaglandins in neurological disease. Abstract Text:

X Liang,L Wu,Q Wang,T Hand,M Bilak,L McCullough,K Andreasson,

Induction of COX-2 expression and enzymatic activity promotes neuronal injury in a number of models of neurological disease. Inhibition of COX-2 activity, either genetically or pharmacologically, has been shown to be neuroprotective in rodent models of stroke, Parkinson's disease, and amyotrophic lateral sclerosis. Inhibition of COX activity with nonsteroidal anti-inflammatory drugs (NSAIDs) reduces inflammation and amyloid accumulation in murine transgenic models of Familial Alzheimer's disease, and the use of NSAIDs decreases the risk of developing Alzheimer's disease in healthy aging populations. COX-mediated neuronal injury is presumed be due to downstream effects of one or more prostaglandin products including PGE2, PGD2, PGF2alpha, PGI2 (prostacylin) and TXA2 (thromboxane) that effect cellular changes through activation of specific prostaglandin receptor subtypes and second messenger systems. In this proceeding, we review recent data demonstrating effects of prostaglandin signaling on neuronal viability that are paradoxically protective, when taken in the context that COX-2 induces neuronal injury in the setting of excitotoxicity. Conversely, in the context of an inflammatory stimulus, the EP2 receptor enhances neuronal injury. These findings argue for an additional level of complexity in the prostaglandin response in neurological disease.

Function of COX-2 and prostaglandins in neurological disease. Publishing Authors By Initials

X Liang,L Wu,Q Wang,T Hand,M Bilak,L McCullough,K Andreasson,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Function of COX-2 and prostaglandins in neurological disease. Journal Published:

PUBLICATION TYPE: Research Support, Non-U.S. Gov

Journal: Journal of molecular neuroscience : MN

VOLUME: 33

Page Numbers: 94-9

Journal Abbreviation: J. Mol. Neurosci.

ISSN: 0895-8696

DAY: 28

MONTH: Sep

YEAR: 2007

Function of COX-2 and prostaglandins in neurological disease. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 9002991

Function of COX-2 and prostaglandins in neurological disease. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Function of COX-2 and prostaglandins in neurological disease. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Function of COX-2 and prostaglandins in neurological disease.

AFFILIATION: Department of Neurology, Johns Hopkins University School of Medicine, 600 N. Wolfe Street, Baltimore, MD 21205, USA.

Country: United States

AGENCY: United States NINDS

GRANT: NS045727

ACRONYM: NS

MEDLINETA: J Mol Neurosci

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Function of COX-2 and prostaglandins in neurological disease Related Publications

• Autoantibodies against bestrophin in a patient with vitelliform paraneoplastic retinopathy and a metastatic choroidal malignant melanoma.
• Different clinical expressions in two families with Stargardt's macular dystrophy (STGD1).
• Effects of a community-based drug use prevention program targeting licensed premises.
• Enrichment of phosphoproteins and phosphopeptide derivatization identify universal stress proteins in elicitor-treated Arabidopsis.
• Fluorescein angiography versus ERG for predicting the prognosis in central retinal vein occlusion.
• Full-field ERG, multifocal ERG and multifocal VEP in patients with retinitis pigmentosa and residual central visual fields.
• Function of COX-2 and prostaglandins in neurological disease.
• Individual, group and community risk and protective factors for alcohol and drug use among Swedish adolescents.
• Macular appearance by means of OCT and electrophysiology in members of two families with different mutations in RDS (the peripherin/RDS gene).
• Misoprostol, an anti-ulcer agent and PGE(2) receptor agonist, protects against cerebral ischemia.
• Multifocal electroretinography and optical coherence tomography in two patients with solar retinopathy.
• Photoswitched DNA-Binding of a Photochromic Spiropyran.
• Rapid decline of JAK2V617F levels during hydroxyurea treatment in patients with polycythemia vera and essential thrombocythemia.
• Reduced full-field electroretinogram (ERG) in a patient treated with methotrexate.
• Regional differences in alcohol consumption, alcohol addiction and drug use among Swedish adults.
• Retinal dysfunction and anterior segment deposits in a patient treated with rifabutin.
• The 30-Hz flicker cone ERG for monitoring the early course of central retinal vein occlusion.
• The prostaglandin E2 EP2 receptor accelerates disease progression and inflammation in a model of amyotrophic lateral sclerosis.